Back to Search

AIMEE SEIDMAN, M.D.

M.D.

Geriatric Medicine (Internal Medicine) Physician

NPI: 1194797225IndividualAccepts Medicare

Specialties, Licenses & Credentials

Geriatric Medicine (Internal Medicine) PhysicianPrimary

Internal Medicine — Geriatric Medicine

Code: 207RG0300X

D37801(MD)

CMS Specialties

PrimaryINTERNAL MEDICINE

Education

OTHER

Class of 1987

Research & Publications (20)

Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes.
PMID 19596644·Clin Breast Cancer·2009
6-review
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects.
PMID 19253021·J Cancer Res Clin Oncol·2009
3-trial
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
PMID 18323546·J Clin Oncol·2008
3-trial
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
PMID 18375893·J Clin Oncol·2008
3-trial
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
PMID 18509177·J Clin Oncol·2008
8-other
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
PMID 19047117·Clin Cancer Res·2008
3-trial
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
PMID 18650151·Clin Breast Cancer·2008
6-review
Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer.
PMID 18078353·Mol Diagn Ther·2007
6-review
Taxanes in breast cancer: an update.
PMID 17164044·Curr Oncol Rep·2007
6-review
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
PMID 17200358·Clin Cancer Res·2007
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
15020 SHADY GROVE RD, SUITE 300
ROCKVILLE, MD 20850

Quick Facts

NPI
1194797225
Entity Type
Individual
Gender
Female
Medicare
Accepted
Specialties
1
Locations
1
Years in Practice
39
Publications
20

Are you this provider?

Claim Your Profile